Shopping Cart
- Remove All
Your shopping cart is currently empty
KRAS inhibitor-32
😃Good
Catalog No. T200688Cas No. 3056974-05-8
KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.
KRAS inhibitor-32
😃Good
Catalog No. T200688Cas No. 3056974-05-8
KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
Bulk & Custom
Questions
View MoreInhibitors Related to "KRAS inhibitor-32"
CASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Ketoconazole
Cited
Xolegel, R-41400, Extina, (±)-Ketoconazol
T067965277-42-1
Ketoconazole (R-41400), a CYP3A4 inhibitor, is an imidazole anti-fungal agent.
- $33
Size
QTY
CitedDeltarasin
T64621440898-61-2In house
Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with Kd of 38 nM for binding to purified PDEδ.
- $38
Size
QTY
Cysmethynil
T36082851636-83-4
Cysmethynil is an indole-based time-dependent inhibitor of Icmt with antitumour activity and inhibitory effects on RAS membrane-binding and EGF signalling.Cysmethynil induces cell cycle arrest in G1 phase and induces cellular autophagy, and can be used for the study of solid tumours.
- $39
Size
QTY
(S)-(-)-Perillyl alcohol
T828218457-55-1
(S)-(−)-Perillyl alcohol (Perillyl alcohol), a monoterpene found in lavender, inhibits Ras farnesylation, upregulates the mannose-6-phosphate receptor, induces apoptosis, and exhibits anti-cancer activity.
- $31
Size
QTY
RMC6236
T746982765081-21-6
RMC-6236 is an orally effective and novel triple complex RAS (ON) MULTI inhibitor, which is a potent non covalent inhibitor of multiple RAS variants in GTP binding state. RMC-6236 has anti-tumor activity and can be used in research related to RAS driven tumors. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.
- $58
Size
QTY
CCG-203971
CCG203971
T43061443437-74-8
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
- $48
Size
QTY
Salirasib
S-Farnesylthiosalicylic acid, FTS, Farnesyl Thiosalicylic Acid
T6163162520-00-5
Salirasib (Farnesyl Thiosalicylic Acid)(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.
- $30
Size
QTY
Rhosin hydrochloride
T167451281870-42-5
Rhosin hydrochloride is a specific inhibitor of the RhoA subfamily Rho GTPases and inhibits the RhoA-GEF interaction. Rhosin hydrochloride can significantly induce cell apoptosis without affecting cell cycle progression. [1]
- $162
Size
QTY
CCG-257081
MRTF/SRF-IN-1, CCG257081, CCG 257081
T307781922098-90-5In house
CCG-257081 (MRTF/SRF-IN-1) is an inhibitor of cardiac myosin-related transcription factor and serum response factor (MRTF/SRF) that acts by inhibiting the Rho/MRTF/SRF pathway.CCG-257081 has shown efficacy in preventing bleomycin-induced fibrosis in several mouse models. CCG-257081 can be used in cancer prevention and fibrosis research.
- $129
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research. |
| Molecular Weight | 622.78 |
| Formula | C29H35FN10OS2 |
| Cas No. | 3056974-05-8 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy KRAS inhibitor-32 | purchase KRAS inhibitor-32 | KRAS inhibitor-32 cost | order KRAS inhibitor-32 | KRAS inhibitor-32 chemical structure | KRAS inhibitor-32 formula | KRAS inhibitor-32 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.